High-Dose Intravenous Corticosteroids
For this patient presenting with acute optic neuritis and transverse myelitis consistent with a demyelinating disease (likely multiple sclerosis), the next step is high-dose intravenous methylprednisolone (1000 mg daily for 3-5 days). This is the established first-line treatment for acute demyelinating attacks affecting the optic nerve and spinal cord 1, 2.
Clinical Reasoning
This 35-year-old woman presents with classic features of a demyelinating disease:
- Optic neuritis: Blurry vision with retro-orbital pain on eye movement
- Transverse myelitis: Bilateral leg weakness with spinal cord T2 hyperintensities
- Relapsing course: Prior episode of hand numbness 6 months ago
- MRI findings: T2 hyperintensities in optic nerve and spinal cord, plus T1 hypointense lesions (residual plaques) indicating chronicity
This constellation strongly suggests multiple sclerosis or a related demyelinating disorder.
Treatment Algorithm
First-Line Treatment (Current Indication)
- Methylprednisolone 1000 mg IV daily for 3-5 days 1, 2
- This should be initiated promptly—delay beyond 2 weeks is associated with worse neurological outcomes 2
- Expected response: Visual improvement within days to 3 weeks; 95% of optic neuritis cases show recovery 3
When to Consider Second-Line Therapies
Plasmapheresis or IVIG should be reserved for:
- Steroid-resistant cases: No improvement or worsening after 3-5 days of high-dose IV corticosteroids 4
- Severe presentations: Profound visual loss (visual acuity <20/80 or 0.6 logMAR) despite corticosteroids 5, 6
- High suspicion for neuromyelitis optica: Longitudinally extensive spinal cord lesions (>3 segments), bilateral optic nerve involvement, or posterior optic nerve/chiasm involvement 2, 7
Comparative Efficacy of Second-Line Options
If steroids fail, the evidence shows:
- IVIG may be superior to plasmapheresis for steroid-resistant optic neuritis: 77% vs 45% significant visual recovery 5
- Both are more effective than corticosteroids alone (30% recovery) 5
- For myelitis specifically: The combination of IV methylprednisolone plus IV cyclophosphamide is recommended if used promptly 2
Critical Pitfalls to Avoid
Do not start with plasmapheresis or IVIG: These are second-line therapies. Starting with them bypasses the proven first-line treatment and delays appropriate care 1, 2, 5
Do not delay treatment: Prompt initiation of IV steroids (within hours to days) is associated with better outcomes. Delays beyond 2 weeks correlate with worse neurological deficits 2
Do not use oral corticosteroids alone: While oral prednisone may speed recovery, IV methylprednisolone is the standard for acute severe demyelinating attacks 3
Monitor for red flags suggesting neuromyelitis optica:
Post-Acute Management
After the acute attack is controlled:
- Taper steroids over 4-6 weeks 4
- Assess MS risk: Brain MRI findings determine future MS risk 3
- Consider disease-modifying therapy: Beta-interferon or glatiramer acetate for high-risk patients 3
- Maintenance immunosuppression: May be needed given the relapsing course and spinal cord involvement (50-60% relapse rate during steroid taper) 2
The evidence consistently supports high-dose IV corticosteroids as first-line treatment, with plasmapheresis or IVIG reserved for steroid-refractory cases or specific high-risk scenarios.